Tilator, I have to totally disagree with you on this one. The worse thing this company ever did was expand the manufacturing capabilities. Generics is tough and tight business to break into. You would need a massive sales force as well as a massive network for distribution. was involved with a company which was breaking into the market with NDA's. on average their sales force and distribution was well over 100 million ! it took 2 full years to just break even.
The company needs to get back to its original business model. which is designing hard to make medications then partner them out for either profit sharing and or licensing out the technology.
Under this model you get the best of both worlds. Odidi is a brilliant scientist. Your overhead is negligible,needing only labs and low amount of workers. As soon as you obtain the approvals the partnerships start bringing in revenue, which is self sustaining of the modest operations and gives you a chance to move onto your next invention.
The reason this business model failed is Odidi. once he invented the technology he is unwilling to follow through with the next step which is partner it out. I personally think ts a bad taste left in him with Biovail, where they used him and he got got nothing in return yet he made the rest rich. Now he is afraid by partnering they will steal his technology. all of a sudden, instead of partnering his inventions he started changing gears and thought he could manufacturer himself. why? because he doesn't trust anyone with the technology! while this may work with the generics, it will never work with Rexista, Regabatin and now even Podras technology. which is why we haven't seen any partnerships!
we need to get Odidi to realize we will never be a major pharmaceutical. we could be a huge technology giant however! He needs to secure his patents, develop the drugs and then partner. from that point on, rely on the legal system to take to court any company, which steal his technology.
Regabatin has been sitting idle for 2 years waiting on a partner. Rexista, with what they filed, could have been filed 2 years ago! Podras only needs to be proven in animals and it could be licensed out for hundreds of other drugs to start NDA supplements ! partnerships with those 3 would generate at least 50 million up front giving more than enough money to allow Odidi to sit in the comfort of his lab to develop the next Podras! and then the upcoming royalties and future milestone payments even more!
we certainly do not need to be adding to overhead to try and go it alone in the generic market. All the man needs to do is get back to his original business model!
